Christopher Jordan Patriquin

Christopher Jordan Patriquin

Auto-generated profile, based on publicly available information

Christopher Jordan Patriquin

Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CPChristopher J. Patriquin
Christopher J. Patriquin
VLVincent Laroche
Vincent Laroche
RSRita Selby
Rita Selby
JPJacob Pendergrast
Jacob Pendergrast
DBDavid Barth
David Barth
JMJohnathan P. Mack
Johnathan P. Mack
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is characterized by thrombosis and thrombocytopenia that occurs 5 to 30 days after ChAdOx1 nCoV-19 vaccination and is associated with heparin-independent platelet factor 4 (PF4) antibodies.1-3 Mortality from VITT is approximately 30 to 60%.1-3 PF4 enzyme-linked immunosorbent assays (ELISAs) in the absence of heparin may be diagnostic; however, functional testing (e.g., serotonin release assay with added PF4 [PF4 SRA]) is recommended.1-4 Initial treatment includes nonheparin anticoagulation and high-dose intravenous immune globulin (IVIG). The treatment that should be used for patients with VITT that does not respond to initial treatment remains unclear.

22 September 2018 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
CPChristopher J. Patriquin
Christopher J. Patriquin
TKThomas Kiss
Thomas Kiss
SCStephen Caplan
Stephen Caplan
ICIan Chin‐Yee
Ian Chin‐Yee
KGKuljit Grewal
Kuljit Grewal
BLBrian Leber
Brian Leber
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease characterized by intravascular hemolysis, thrombophilia, and marrow failure. Its phenotype is due to absent or reduced expression of GPI‐linked complement regulators and subsequent sensitivity of hematopoietic cells to complement‐mediated damage and lysis. Introduction of the terminal complement inhibitor eculizumab drastically improved outcomes in PNH patients; however, despite this improvement, there remain several challenges faced by PNH patients and physicians who care for them. One of the most important is increasing awareness of the heterogeneity with which patients can present, which can lead to significant delays in recognition. Data from the Canadian PNH Registry are presented to demonstrate the variety of presenting symptoms. In Canada, geography precludes consolidation of care to just a few centers, so management is distributed across academic hospitals, linked together as the Canadian PNH Network. The Network over the last several years has developed educational programs and clinical checklists and has worked to standardize access to diagnostics across the country. Herein, we address some of the common diagnostic and therapeutic challenges faced by PNH physicians and give our recommendations. Gaps in knowledge are also addressed, and where appropriate, consensus opinion is provided.

1 October 2019 in Transfusion Medicine Reviews
Verified
Journal Article
Closed access
CPChristopher J Patriquin
Christopher J Patriquin
KKKevin H.M. Kuo
Kevin H.M. Kuo

1 December 2023 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
MOMonika Oliver
Monika Oliver
CPChristopher J Patriquin
Christopher J Patriquin
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare, acquired clonal abnormality, which renders hematopoietic cells exquisitely sensitive to complement-mediated destruction. Classical features of PNH include intravascular hemolytic anemia, increased thrombotic risk, and manifestations related to end-organ damage (eg fatigue, chest pain, dyspnea, renal failure, and pulmonary hypertension). With supportive care alone, mortality rate of patients with PNH is approximately 35%. The anti-C5 monoclonal antibody, eculizumab, was the first targeted therapy approved for PNH, and led to improved hemoglobin, quality of life, reduced transfusion need, reduced thrombosis, and greater overall survival. More recently, therapeutics such as longer acting anti-C5 (ravulizumab) and anti-C3 (pegcetacoplan) medications have been approved, along with other novel therapeutics in late-stage clinical trials. Biosimilars of eculizumab are also now available. Proximal inhibitors (against C3, factor B, and factor D) have shown significant improvements in hemoglobin and transfusion-avoidance in patients who remain anemic despite C5 inhibition. Despite these novel therapies, some unmet challenges remain, including management of breakthrough hemolysis, clinically significant iatrogenic extravascular hemolysis, optimal management in pregnancy, and infection risk mitigation as new targets in the complement system are blocked. In addition, the use of self-administered subcutaneous and oral therapies raises concerns around treatment adherence and the risks of uncontrolled terminal complement. Given the ultra-rare nature of PNH, development is underway of a centralized international registry to capture and analyze the data as they mature for various new therapies and characterize the clinical challenges related to PNH management.

20 February 2025 in Blood
Verified
Journal Article
Open access
AKAustin Kulasekararaj
Austin Kulasekararaj
MGMorag Griffin
Morag Griffin
CPCaroline Piatek
Caroline Piatek
JSJamile Shammo
Jamile Shammo
JNJun-Ichi Nishimura
Jun-Ichi Nishimura
JLJong Wook Lee
Jong Wook Lee
Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic due to clinically significant extravascular hemolysis (cs-EVH; hemoglobin [Hb] ≤9.5 g/dL and absolute reticulocyte count [ARC] ≥120 × 109/L). In the phase 3 ALPHA trial, participants received oral factor D inhibitor danicopan (150 mg 3 times daily) or placebo plus ravulizumab or eculizumab during the 12-week, double-blind treatment period 1 (TP1); those receiving placebo switched to danicopan during the subsequent 12-week, open-label TP2 and continued during the 2-year long-term extension (LTE). There were 86 participants randomized in the study, of whom 82 entered TP2, and 80 entered LTE. The primary end point was met, with Hb improvements from baseline at week 12 (least squares mean change, 2.8 g/dL) with danicopan. For participants switching from placebo to danicopan at week 12, improvements in mean Hb were observed at week 24. Similar trends were observed for the proportion of participants with ≥2 g/dL Hb increase, ARC, proportion of participants achieving transfusion avoidance, and Functional Assessment of Chronic Illness Therapy–Fatigue scale scores. Improvements were maintained up to week 72. No new safety signals were observed. The breakthrough hemolysis rate was 6 events per 100 patient-years. These long-term data demonstrate sustained efficacy and safety of danicopan plus ravulizumab/eculizumab for continued control of terminal complement activity, intravascular hemolysis, and cs-EVH in PNH. This trial was registered at www.clinicaltrials.gov as #NCT04469465.

15 September 2023 in European Journal of Haematology
Verified
Journal Article
Open access
LTLouis Terriou
Louis Terriou
JLJong Wook Lee
Jong Wook Lee
CFCecily Forsyth
Cecily Forsyth
MGMorag Griffin
Morag Griffin
Jeff SzerJeff Szer
Jeff Szer
CPChristopher J. Patriquin
Christopher J. Patriquin
Objectives: Data from the International PNH Registry (NCT01374360) were used to estimate the overall survival and first occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) for eculizumab‐treated patients with paroxysmal nocturnal hemoglobinuria (PNH) compared with a contemporaneous untreated cohort.Methods: Patients enrolled in the Registry from March 16, 2007, to February 14, 2022, were included. Treated patients received eculizumab for >35 days; untreated patients did not receive eculizumab at any time. Univariable and multivariable analyses were performed using a Cox proportional hazards regression model comparing eculizumab treatment periods to untreated periods and were adjusted for baseline covariates (e.g., high disease activity [HDA], transfusion dependency, and eculizumab treatment status).Results: The analysis included 4118 patients. The univariable hazard ratio (HR) (95% CI) for mortality in eculizumab‐treated time versus untreated time was 0.51 (0.41–0.64; p < 0.0001). Significant baseline covariates included age, sex, history of bone marrow failure, ≥4 erythrocyte transfusions within 12 months before baseline, and an estimated glomerular filtration rate ≤ 60 mL/min/1.73 m2 (all p < 0.0001). In the adjusted analysis, patients with baseline HDA had the greatest reduction in mortality risk (HR [95% CI], 0.51 [0.36–0.72]). Treated patients had approximately 60% reduction in TE/MAVE risk during treated versus untreated time (HR [95% CI]: TE: 0.40 [0.26–0.62], MAVE: 0.37 [0.26–0.54]; p < 0.0001).Conclusion: Using data from the largest Registry of patients with PNH, with ≥14 years of overall follow‐up, we demonstrate that treatment with eculizumab conferred a 49% relative benefit in survival and an approximately 60% reduction in TE/MAVE risk.